Revvity/$RVTY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Revvity
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
Ticker
$RVTY
Sector
Primary listing
NYSE
Employees
11,000
Headquarters
Website
Revvity Metrics
BasicAdvanced
$11B
48.43
$1.99
0.99
$0.28
0.29%
Price and volume
Market cap
$11B
Beta
0.99
52-week high
$128.29
52-week low
$81.36
Average daily volume
1.3M
Dividend rate
$0.28
Financial strength
Current ratio
1.753
Quick ratio
1.318
Long term debt to equity
37.76
Total debt to equity
45.676
Dividend payout ratio (TTM)
14.06%
Interest coverage (TTM)
4.54%
Profitability
EBITDA (TTM)
822.468
Gross margin (TTM)
55.27%
Net profit margin (TTM)
8.44%
Operating margin (TTM)
14.76%
Effective tax rate (TTM)
14.30%
Revenue per employee (TTM)
$260,000
Management effectiveness
Return on assets (TTM)
2.08%
Return on equity (TTM)
3.04%
Valuation
Price to earnings (TTM)
48.429
Price to revenue (TTM)
4.064
Price to book
1.51
Price to tangible book (TTM)
-6.75
Price to free cash flow (TTM)
22.989
Free cash flow yield (TTM)
4.35%
Free cash flow per share (TTM)
4.195
Dividend yield (TTM)
0.29%
Forward dividend yield
0.29%
Growth
Revenue change (TTM)
3.37%
Earnings per share change (TTM)
-3.30%
3-year revenue growth (CAGR)
-7.88%
10-year revenue growth (CAGR)
2.20%
3-year earnings per share growth (CAGR)
-26.33%
10-year earnings per share growth (CAGR)
2.57%
What the Analysts think about Revvity
Analyst ratings (Buy, Hold, Sell) for Revvity stock.
Bulls say / Bears say
Revvity exceeded Q1 estimates with adjusted EPS of $1.01 versus $0.95 and revenue of $664.8 million versus $661.2 million, supported by consistent biotech demand, and raised its 2025 revenue guidance to $2.83 billion–$2.87 billion (Reuters).
For Q2 2025, Revvity reported adjusted EPS of $1.18, beating the $1.14 consensus, and revenue of $720.3 million, above the $710.4 million estimate, demonstrating strong operational performance (Barron’s).
More than half of Revvity’s revenue comes from international markets, and a weaker U.S. dollar gave a foreign exchange boost that helped justify its increased revenue outlook (Reuters).
Revvity’s Q2 adjusted operating margin fell to 26.6% from 28.8% year-over-year, indicating profitability is under pressure from higher costs (Barron’s).
The company lowered its full-year adjusted EPS guidance to $4.85–$4.95 from the previous $4.90–$5.00, coming in below the analyst consensus of $4.93, pointing to potential earnings headwinds (Barron’s).
Revvity highlighted a “meaningful pullback” in its immunodiagnostics business in China after DRG-related reimbursement changes triggered a double-digit sales drop, which caused shares to fall nearly 10% (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
Revvity Financial Performance
Revenues and expenses
Revvity Earnings Performance
Company profitability
Revvity News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Revvity stock?
Revvity (RVTY) has a market cap of $11B as of October 29, 2025.
What is the P/E ratio for Revvity stock?
The price to earnings (P/E) ratio for Revvity (RVTY) stock is 48.43 as of October 29, 2025.
Does Revvity stock pay dividends?
Yes, the Revvity (RVTY) stock pays dividends to shareholders. As of October 29, 2025, the dividend rate is $0.28 and the yield is 0.29%. Revvity has a payout ratio of 14.06% on a trailing twelve-month basis.
When is the next Revvity dividend payment date?
The next Revvity (RVTY) dividend payment is scheduled for November 07, 2025.
What is the beta indicator for Revvity?
Revvity (RVTY) has a beta rating of 0.99. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.